AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) said their jointly developed breast cancer therapy ENHERTU has ...

Individuals with CD who received treatment with biologics preoperatively have improved endoscopic outcomes when switching to a different biologic postoperatively.

A new tool can help physicians determine which patients with localized pancreatic neuroendocrine tumors (PanNETs) have an ...

James Stewart puts on his rollerblades to get ready to do the trail in Rabb Park on his day off. He continues to be able to ...

Investigators compared patient-reported cancer-related cognitive impairment between pre- and postmenopausal women with breast cancer who received endocrine therapy with or without chemotherapy.

A new risk score can help predict which pancreatic cancer survivors are more likely to suffer a recurrence of their cancer, researchers said.

A new risk score may identify patients with node-negative pancreatic neuroendocrine tumors who face a high risk for recurrence after surgery.

The score could help better manage the follow-up care for patients who’ve had pancreatic tumors surgically removed, and whose cancers have not spread to their lymph nodes, researchers wrote Dec. 17 in ...

The 13-point risk score can help doctors more closely monitor patients at higher risk About 10% of patients suffer a cancer recurrence, most often in their liver FRIDAY, Dec. 19, 2025 (HealthDay News) ...

Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients with pancreatic neuroendocrine tumors (PanNETs) need closer monitoring ...